Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 1/20 | 0.40 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 2/20 | 0.36 |
| ▸ | ACE | P12821 | 2/20 | 0.36 |
| ▸ | ECE1 | P42892 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7150098 | 0.88 | FABP1 (0.42) | TSHRHCRTR1KMT2ATHRB | |
| SCHEMBL7143747 | 0.87 | KMT2A (0.41) | MMEACEECE1KMT2ALMNA | |
| SCHEMBL7145955 | 0.86 | RAB9A (0.38) | MMEACEECE1HCRTR1KMT2A | |
| SCHEMBL7150389 | 0.86 | TAOK1 (0.33) | MMEACEECE1SLC16A3KMT2A | |
| SCHEMBL7142485 | 0.85 | ECE1 (0.53) | CCR4MMEACEECE1HCRTR1 | |
| SCHEMBL7150469 | 0.85 | MME (0.43) | CCR4NR1D1TSHRMMEACE | |
| SCHEMBL7150463 | 0.85 | MME (0.43) | CCR4NR1D1TSHRMMEACE | |
| SCHEMBL7143169 | 0.84 | KMT2A (0.41) | MMEACEECE1KMT2A | |
| SCHEMBL7139383 | 0.82 | HSD17B10 (0.37) | CCR4TSHRMMEACEECE1 | |
| SCHEMBL7149181 | 0.82 | LMNA (0.39) | KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6541638-B2 | (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction | HOFFMAN-LA ROCHE INC. | 2003-04-01 | — | — | US | disclosed |
| US-20020049243-A1 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049243-A1 | Pyrrolidine derivatives | PREP, PEPD, DNPEP | CCR4 2784/4885NR1D1 1252/4885TSHR 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.